These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 33408844)

  • 1. The molecular pathogenesis of multiple myeloma.
    Bolli N; Martinelli G; Cerchione C
    Hematol Rep; 2020 Dec; 12(3):9054. PubMed ID: 33408844
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genomics of Smoldering Multiple Myeloma: Time for Clinical Translation of Findings?
    Lionetti M; Da Vià MC; Albano F; Neri A; Bolli N; Musto P
    Cancers (Basel); 2021 Jul; 13(13):. PubMed ID: 34282760
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnosis, risk stratification and management of monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
    van de Donk NW; Mutis T; Poddighe PJ; Lokhorst HM; Zweegman S
    Int J Lab Hematol; 2016 May; 38 Suppl 1():110-22. PubMed ID: 27161311
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clonal Evolution of Multiple Myeloma-Clinical and Diagnostic Implications.
    Salomon-Perzyński A; Jamroziak K; Głodkowska-Mrówka E
    Diagnostics (Basel); 2021 Aug; 11(9):. PubMed ID: 34573876
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Pathogenesis of multiple myeloma].
    Rasche L; Weinhold N
    Internist (Berl); 2019 Jan; 60(1):3-9. PubMed ID: 30536029
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Progress in the Management of Smoldering Multiple Myeloma.
    Schmidt TM; Callander NS
    Curr Hematol Malig Rep; 2021 Apr; 16(2):172-182. PubMed ID: 33983517
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single cell clonotypic and transcriptional evolution of multiple myeloma precursor disease.
    Dang M; Wang R; Lee HC; Patel KK; Becnel MR; Han G; Thomas SK; Hao D; Chu Y; Weber DM; Lin P; Lutter-Berka Z; Berrios Nolasco DA; Huang M; Bansal H; Song X; Zhang J; Futreal A; Moreno Rueda LY; Symer DE; Green MR; Rojas Hernandez CM; Kroll M; Afshar-Khargan V; Ndacayisaba LJ; Kuhn P; Neelapu SS; Orlowski RZ; Wang L; Manasanch EE
    Cancer Cell; 2023 Jun; 41(6):1032-1047.e4. PubMed ID: 37311413
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advances in MGUS diagnosis, risk stratification, and management: introducing myeloma-defining genomic events.
    Landgren O
    Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):662-672. PubMed ID: 34889381
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Moving From Cancer Burden to Cancer Genomics for Smoldering Myeloma: A Review.
    Maura F; Bolli N; Rustad EH; Hultcrantz M; Munshi N; Landgren O
    JAMA Oncol; 2020 Mar; 6(3):425-432. PubMed ID: 31830214
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Monoclonal gammopathy of undetermined significance and asymptomatic multiple myelom in the year 2014 ].
    Adam Z; Krejčí M; Pour L; Sevčíková E; Křivanová A; Rehák Z; Koukalová R; Cermáková Z; Vaníček J; Sevčíková S
    Vnitr Lek; 2014 Oct; 60(10):861-79. PubMed ID: 25382009
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changing paradigms in diagnosis and treatment of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM).
    Ho M; Patel A; Goh CY; Moscvin M; Zhang L; Bianchi G
    Leukemia; 2020 Dec; 34(12):3111-3125. PubMed ID: 33046818
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Defining genomic events involved in the evolutionary trajectories of myeloma and its precursor conditions.
    Chojnacka M; Diamond B; Landgren O; Maura F
    Semin Oncol; 2022 Feb; 49(1):11-18. PubMed ID: 35168813
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cell of Origin and Genetic Alterations in the Pathogenesis of Multiple Myeloma.
    Barwick BG; Gupta VA; Vertino PM; Boise LH
    Front Immunol; 2019; 10():1121. PubMed ID: 31231360
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 2021 European Myeloma Network review and consensus statement on smoldering multiple myeloma: how to distinguish (and manage) Dr. Jekyll and Mr. Hyde.
    Musto P; Engelhardt M; Caers J; Bolli N; Kaiser M; Van de Donk N; Terpos E; Broijl A; De Larrea CF; Gay F; Goldschmidt H; Hajek R; Vangsted AJ; Zamagni E; Zweegman S; Cavo M; Dimopoulos M; Einsele H; Ludwig H; Barosi G; Boccadoro M; Mateos MV; Sonneveld P; Miguel JS
    Haematologica; 2021 Nov; 106(11):2799-2812. PubMed ID: 34261295
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MGUS and Smoldering Multiple Myeloma: Diagnosis and Epidemiology.
    Mateos MV; Landgren O
    Cancer Treat Res; 2016; 169():3-12. PubMed ID: 27696254
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single-cell profiling of tumour evolution in multiple myeloma - opportunities for precision medicine.
    Dutta AK; Alberge JB; Sklavenitis-Pistofidis R; Lightbody ED; Getz G; Ghobrial IM
    Nat Rev Clin Oncol; 2022 Apr; 19(4):223-236. PubMed ID: 35017721
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma: a review of the current understanding of epidemiology, biology, risk stratification, and management of myeloma precursor disease.
    Agarwal A; Ghobrial IM
    Clin Cancer Res; 2013 Mar; 19(5):985-94. PubMed ID: 23224402
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transcriptome analysis reveals molecular profiles associated with evolving steps of monoclonal gammopathies.
    López-Corral L; Corchete LA; Sarasquete ME; Mateos MV; García-Sanz R; Fermiñán E; Lahuerta JJ; Bladé J; Oriol A; Teruel AI; Martino ML; Hernández J; Hernández-Rivas JM; Burguillo FJ; San Miguel JF; Gutiérrez NC
    Haematologica; 2014 Aug; 99(8):1365-72. PubMed ID: 24816239
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Smoldering multiple myeloma and monoclonal gammopathy of undetermined significance.
    Bladé J; Rosiñol L
    Curr Treat Options Oncol; 2006 May; 7(3):237-45. PubMed ID: 16615879
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-risk smoldering myeloma versus early detection of multiple myeloma: Current models, goals of therapy, and clinical implications.
    Kunacheewa C; Manasanch EE
    Best Pract Res Clin Haematol; 2020 Mar; 33(1):101152. PubMed ID: 32139017
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.